Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $251,210.80 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 19,060 shares of the company’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $13.18, for a total value of $251,210.80. Following the completion of the transaction, the chief operating officer owned 494,920 shares in the company, valued at $6,523,045.60. This represents a 3.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Julie Rubinstein also recently made the following trade(s):

• On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.41, for a total transaction of $255,594.60.
• On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07.
• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.96, for a total value of $247,017.60.
• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.79, for a total value of $457,617.39.
• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.68, for a total value of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.67, for a total value of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.00, for a total value of $495,056.00.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT traded down $0.11 during mid-day trading on Wednesday, reaching $13.28. The stock had a trading volume of 1,550,271 shares, compared to its average volume of 2,051,436. The stock has a market cap of $2.04 billion, a P/E ratio of -33.20 and a beta of 2.19. The business’s 50 day moving average is $16.44 and its 200 day moving average is $15.90. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.68 and a fifty-two week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. The firm had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company’s revenue was up 51.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.23) earnings per share. Equities analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Analyst Ratings Changes

ADPT has been the subject of several analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. JPMorgan Chase & Co. raised their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Ameriprise Financial Inc. increased its stake in Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after acquiring an additional 3,299,635 shares during the period. Westfield Capital Management Co. LP acquired a new stake in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $65,942,000. Geode Capital Management LLC grew its holdings in shares of Adaptive Biotechnologies by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after purchasing an additional 110,825 shares in the last quarter. Finally, State Street Corp increased its position in shares of Adaptive Biotechnologies by 3.3% during the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after purchasing an additional 102,362 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.